ArticleThe Journal of clinical endocrinology and metabolism2023
Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction.
Article in The Journal of clinical endocrinology and metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Incidence of thyroid adverse events following immune checkpoint inhibitor treatment in patients with baseline positive thyroid antibodies: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization.Human vaccines & immunotherapeutics · 2024Pooled it
- Thyroid function and ultrasound surveillance in childhood cancer survivors (CCS): a position paper of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED).Journal of endocrinological investigation · 2026Review
- PD-1 inhibitors combined with tyrosine kinase inhibitor-associated hypothyroidism is a predictive factor for antitumor effectiveness in male patients with hepatocellular carcinoma.Oncology letters · 2026Article
- Vanishing high-risk thyroid nodule following pembrolizumab-induced destructive thyroiditis: case report and focused literature review.Hormones (Athens, Greece) · 2026Review
- Article
- Clinical characteristics and management of PD-1/PD-L1 inhibitor-induced secondary adrenal insufficiency.Endocrine connections · 2026Article
- Organ-metastatic landscape delineates overall and site-specific immune-related adverse events of PD-L1 blockade in advanced NSCLC.NPJ precision oncology · 2026Article
- Immune-Related Thyroid Dysfunction in PD-L1 High Non-Oncogene-Addicted NSCLC Treated with First-Line Pembrolizumab: Incidence, Timing, and Predictive Impact.Current oncology (Toronto, Ont.) · 2026Article
- Associations between Immune-related Adverse Events and Prognosis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy.Internal medicine (Tokyo, Japan) · 2026Review
- Clinical characteristics, management, and prognosis of ipilimumab-induced hypophysitis: a retrospective analysis of 76 cases.Frontiers in endocrinology · 2026Article
- Sex-specific reporting patterns and onset timing of immune-related adverse events associated with nivolumab and pembrolizumab: a dual-database pharmacovigilance analysis.Frontiers in immunology · 2026Article
- Thyroid toxicity in lung cancer patients treated with immune-checkpoint inhibitors: a single-center retrospective analysis.Frontiers in immunology · 2026Article
- Real-world insights into incidence and risk factors of thyroid dysfunction following immune checkpoint inhibitor therapy.Frontiers in immunology · 2026Observational
- Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes.Journal of endocrinological investigation · 2025Review
- Disproportionality analysis and risk factor assessment of drug-associated thyroid dysfunction adverse events: a study based on the FAERS database.Endocrine connections · 2025Article
- Association between platelet-to-lymphocyte ratio and immune checkpoint inhibitor-induced thyroid dysfunction.Endocrine · 2025Observational
- Mapping the genetic-transcriptional landscape of thyroid irAEs in sintilimab therapy: toward biomarker-guided immunotoxicity prediction.Frontiers in immunology · 2025Article
- Pre-existing subclinical hypothyroidism and low free thyroxine in patients undergoing immune checkpoint inhibitor therapies is a risk factor for overt hypothyroidism.Frontiers in endocrinology · 2025Article
- Biomarkers in the early stage of PD-1 inhibitor treatment have shown superior predictive capabilities for immune-related thyroid dysfunction.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextExplore the clinical characteristics and influencing factors of immune thyroid dysfunction (ITD) caused by immune checkpoint inhibitors (ICIs) in the treatment of malignant tumors.
methodsThis was a retrospective study of cancer patients treated with ICIs between January 2019 and December 2021 at the Second Affiliated Hospital of Nanchang University. According to the occurrence of thyroid dysfunction, patients were divided into an ITD group and non-ITD group. We describe the clinical characteristics, autoantibody levels, and their impact on prognosis of patients with ICI-related ITD.
resultA total of 560 cases meeting the criteria were included, with a median follow-up time of 11.0 months. The incidence of ITD was 50.7%. Baseline TSH levels (OR, 1.935/mcIU/L; 95% CI, 1.613-2.321; P < .001) and combination targeted therapy (OR, 2.101; 95% CI, 1.433-3.079; P < .001) were most strongly associated with the occurrence of ITD. The median time to ITD in patients receiving medication with ICIs was 73 (34.5-149) days. Of the 87 patients initially diagnosed with hyperthyroid ITD, 46 (52.9%) progressed to hypothyroidism over the course of the disease. Baseline anti-thyroglobulin antibody abnormalities were strongly associated with the occurrence of ITD (OR, 67.393; 95% CI, 5.637-805.656; P = .001). Overall survival was significantly lower in patients who did not develop ITD than in those who did (hazard ratio, 0.523; 95% CI, 0.599-0.97; P < .001).
conclusionThe incidence of ICI-related ITD is high, and the course of the disease is rapidly changing, and thyroid function in patients treated with immunotherapy should be monitored to detect ITD and permit early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.